Abcam, ab7166, Anti-Integrin alpha V beta 3 antibody [BV3]

Size: 50µg
Anti-Integrin alpha V beta 3 antibody [BV3] (ab7166) is a mouse monoclonal antibody detecting Integrin alpha V beta 3 in Flow Cytometry, IP, IHC-P, IHC-Fr, ICC/IF . Suitable for Chicken, Human, Rat . - Over 20 publications - Trusted since 2002
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:BV3,
Isotype:IgG1,
Carrier free:No,
Reacts with:Rat, Chicken, Human,
Applications:IP, IHC-P, ICC/IF, IHC-Fr, Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Specificity:This monoclonal antibody binds to human CD51 and Cd61 integrins present on human endothelium cells.

Product details:
What is this antibody validated in?
Anti-Integrin alpha V beta 3 antibody [BV3] (ab7166) is a mouse monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunohistochemistry (IHC-Fr), Immunocytochemistry/immunofluorescence (ICC/IF) in Chicken, Human, Rat samples.
Trusted by the scientific community
Anti-Integrin alpha V beta 3 [BV3] (ab7166) was first used in a scientific publication in 2002 and has been cited over 20 times in peer-reviewed journals.
Reviewed by scientists
Anti-Integrin alpha V beta 3 [BV3] (ab7166) has over 5 independent reviews from customers.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein G, Storage buffer-Preservative: 0.1% Sodium azideConstituents: 0.2% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Integrin alpha V beta 3 also known as integrin αvΒ3 or avb3 integrin is a transmembrane receptor with a molecular weight of about 140 kDa. This protein is composed of the alpha V (αv) and beta 3 (Β3) subunits. Integrin αvΒ3 is widely expressed in various cell types including endothelial cells osteoclasts and some tumor cells. Its function involves mechanical interaction with the extracellular matrix (ECM) allowing cells to adhere to ECM proteins such as vitronectin and fibronectin. This integrin plays an important role in cell adhesion migration and survival.
Biological function summary
Integrin alpha V beta 3 engages in various cellular processes by serving as a part of integrin complexes. It mediates signal transduction from the ECM to the cell interior influencing cellular responses such as shape changes survival and proliferation. The receptor regulates angiogenesis which is the formation of new blood vessels and osteoclast-mediated bone resorption. These functions are essential for tissue remodeling and repair. The integrin can also modulate immune responses by interacting with immune cells affecting inflammation and wound healing processes.
Pathways
Integrin alpha V beta 3 is an important component in signaling pathways such as the PI3K/AKT and MAPK pathways. These pathways facilitate the integrin's role in cell migration growth and survival. It interacts with proteins like focal adhesion kinase (FAK) and SRC kinase bridging signals from the ECM to intracellular signaling cascades. The integrin's ability to bind ligands and initiate these pathways makes it an important player in cellular responses to the extracellular environment influencing how cells align mechanically and biochemically.
Integrin alpha V beta 3 has significant associations with cancer progression and osteoporosis. In various cancers including melanoma and breast cancer overexpression of this integrin supports tumor angiogenesis and metastasis connecting its role with angiogenic growth factors and matrix metalloproteinases. In osteoporosis it collaborates with proteins like osteopontin promoting osteoclast attachment to the bone matrix thereby influencing bone degradation. Understanding its role in these disorders highlights potential therapeutic targets for inhibiting unwanted angiogenesis and excessive bone resorption.